News

Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...
Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...
Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...
Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...
Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...
Out of all of the special options we uncovered, 26 are puts, for a total amount of $1,771,839, and 16 are calls, for a total amount of $839,064. Taking into account the Volume and Open Interest on ...
Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...
The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...